ARM's purpose and goal is to accelerate biomedical research aimed at developing treatments for rare genetic disorders more prevalent in Middle Eastern community mainly GNE Myopathy, and skeletal muscle regeneration. GNE Myopathy is also commonly known as Hereditary Inclusion Body Myopathy (HIBM), GNE myopathy, Distal Myopathy with Rimmed Vacuoles (DMRV), Nonaka Myopathy, or Quadriceps Sparing Myopathy (Mendelian Inheritance in Man Catalogue #600737 or #605820). ARM's mission is to accomplish this goal in the most efficient manner possible, with special emphasis on considerations of results/duration/cost value of proposed research.
ARM's vision is to have an effective preventive treatment for HIBM available for all current and future patients in the next few years, to offer regenerative treatments for patients who have lost muscle tissue, and to empower patients, and community, worldwide with knowledge and support.